Tag: Dan Greenleaf
'Disruptors' put a dent in BioScrip's earnings
November 3, 2017Theresa Flaherty, Managing Editor
DENVER - Company officials at BioScrip blamed a second straight quarter of net revenue declines on several “disrupters,” both expected and unexpected.
The declines primarily stem fromBioScrip's exit from a UnitedHealthcare contract and the double whammy of Hurricanes Harvey and Irma, said CEO Daniel Greenleaf, CEO, during a Nov. 2 earnings call.
“Disruption from the hurricanes and the UnitedHealthcare contract transition decreased revenue by an estimated $10 million during...
BioScrip revenues are down, but core product mix is up
August 11, 2017Theresa Flaherty, Managing Editor
DENVER - BioScrip's net revenues decreased 6.2% in the second quarter of 2017, but CEO Dan Greenleaf said in an earnings call the company was hitting targets.BioScrip reported net revenues of $218.1 million for the second quarter of 2017 compared to $232.4 million for the same period a year ago. Net loss was $29.2 million vs. $8.2 million.Still, BioScrip increased its core product mix to 73.1%, compared to 60.3% a year ago, with an ultimate goal of 85%.“Overall, our turnaround plan is on schedule,”...
BioScrip earnings 'in line' with expectations
May 5, 2017HME News Staff
DENVER - BioScrip reported net revenues of $217.8 million for the first quarter of 2017, reflecting a core revenue mix of 72% compared to 60% during the same quarter in 2016. Net loss was $19 million and adjusted EBITD was 5.2 million. For the full year 2017, BioScrip expects to achieve adjusted EBITDA in the range of $45 million to $55 million. “I am pleased with our company's first quarter performance, which was in line with our plan,” said Dan Greenleaf, president and CEO in a press...
'Clear mission' says Greenleaf
March 22, 2017Theresa Flaherty, Managing Editor
With one full financial quarter under his belt, BioScrip President and CEO Dan Greenleaf says the company is reinvigorated and on track to right itself.“We've got a highly engaged organization that is very clear about the mission of the organization,” said Greenleaf, who took the reins in September after several disappointing quarters for the company. “We aren't firing on all cylinders yet, but I would submit we are firing on most.”A key tenet of BioScrip's turnaround plan...
CORE is key to BioScrip reversal
March 10, 2017Theresa Flaherty, Managing Editor
DENVER - BioScrip has pushed closer to its goal of having its core home infusion business make up 85% of its overall revenue, said company executives on a recent earnings call.On March 3, BioScrip reported net revenues of $166.8 million for its core business for the fourth quarter, an increase of $21.9 million or 15.1% compared to the same quarter in 2015. The core business grew to represent 70% of the company's total revenues in the quarter.“We've got a great sales team in place, and some...
BioScrip restructures credit
December 14, 2016HME News Staff
DENVER - BioScrip has announced a plan to increase its liquidity.
The home infusion and home care provider has proposed an amendment to its original credit agreement that would restructure an existing revolving credit facility, providing immediate access to $15 million.
BioScrip has suffered losses in recent quarters. Net revenues for the third quarter of 2016 were $224.5 million, a decrease of 9.2% from a year ago. Net losses from continuing operations were $11.1 million vs. $24.5 million.
The...
Turnaround king?
November 23, 2016Theresa Flaherty, Managing Editor
Daniel Greenleaf is in a familiar position. The new president and CEO of BioScrip is tasked with turning around an underperforming home infusion company, which he did with both Coram and, more recently, with Home Solutions.
“Under my leadership, my team and I developed and led transformational change resulting in Home Solutions becoming one of the top performing infusion services providers n the country,” said Greenleaf during a recent earnings call. “I see many similarities between...
BioScrip 'took its eye off the ball'
November 11, 2016Theresa Flaherty, Managing Editor
DENVER - With revenues at BioScrip sliding again in the third quarter, new President and CEO Daniel Greenleaf didn't mince words on a recent earnings call.
“Clearly, the organization took its eye off the ball in the third,” he said. “The people that were involved are no longer part of the organization in any way, shape or form.”
Greenleaf took the reins in September when BioScrip completed its acquisition of HS Holdings, where he had served as CEO since 2014. Prior...
Greenleaf: 'Home infusion is a valuable option'
June 20, 2014Theresa Flaherty, Managing Editor
In his six years in the home infusion business, Dan Greenleaf has seen his share of challenges. Still, the new CEO of Home Solutions says it's an exciting place to be. He spoke with HME News recently about home infusion's role in the “medical neighborhood.”HME News: Why is this an exciting time for home infusion?Dan Greenleaf: We have a broken healthcare system in the sense that we are treating patients extremely inefficiently. The home is the preferred choice for the patient, for the...
In brief: Stakeholders keep eye on doc fix, CMS issues refunds
December 6, 2013HME News Staff
WASHINGTON - As this year's congressional session winds down, HME stakeholders are eyeing the “doc-fix” bill as the best vehicle for H.R. 1717. The Senate Finance and House Ways and Means committees are expected to mark up the doc fix bill on Thursday, according to Cara Bachenheimer, senior vice president of government relations for Invacare. If a finalized fix to physician reimbursement is delayed, it would give the industry more time to push H.R. 1717, which has 160 co-sponsors,...